Pyrrole Antiviral Compounds for Hepatitis B and D Replication Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hepatitis B and hepatitis D infections are inadequate, as they do not cure the infections but only suppress virus replication, and hepatitis D has a high fatality rate with no cure or vaccine available.

Innovation Solution

Development of pyrrole compounds or their pharmaceutically acceptable salts for use in treating hepatitis B and D infections, including methods of administration and inhibition of viral replication.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If approved drugs are used to treat HBV by boosting immune system or slowing viral replication, then viral replication is suppressed, but the infections are not cured and continue to be a problem

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to cure infection

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by developing novel pyrrole compounds with specific chemical structures (Formula I) that differ from existing approved drugs. These compounds represent a change in the chemical parameter space, exploring new molecular structures with potentially different mechanisms of action that could achieve both viral suppression and cure

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent segments the treatment approach by targeting different stages or aspects of the viral lifecycle through specific pyrrole compound structures. The diversified chemical structures (with various R1, R2, R3, R4 substituents) suggest targeted interventions at multiple points in the viral replication process, moving beyond single-mechanism suppression to multi-faceted treatment that could lead to cure

Inventive Principle:

Principle #1Segmentation

2Reliability

If current treatments are used for hepatitis D, then viral replication is suppressed, but the high fatality rate and lack of cure remain unresolved

Engineering Contradiction:

Improvesuppression of viral replicationVSAvoidfatality rate and severity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of HDV replication into a beneficial treatment outcome by using pyrrole compounds that specifically target and inhibit this replication. The compounds transform the pathological process into a controlled therapeutic response, reducing fatality and severity while achieving viral suppression

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent employs composite chemical structures in the pyrrole compounds (combining core pyrrole ring with various substituents R1-R4) to create molecules with enhanced therapeutic properties. This composite molecular design aims to achieve both viral suppression and reduction of disease severity/fatality simultaneously

Inventive Principle:

Principle #40Composite materials

Data Source

PatentEP3947349B1Pyrrole compounds

Publication Date: 2026.03.11 ALIGOS THERAPEUTICS INC

AI summary

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.